Ftse Mib
39.224,71
1,32%
DAX
22.794,11
1,78%
S&P 500
5.956,06
0,01%
NASDAQ
19.075,26
0,26%
Bitcoin
85.065,04
1,18%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Plus Therapeutics Inc (PSTV) Plus Therapeutics Inc (PSTV) Notizie

Plus Therapeutics Inc

PSTV
0,7825
-0,2975 (-27,55%)
27 Feb 2025 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
26/2/202513:30GLOBEPlus Therapeutics Advances Lead Drug Rhenium (186Re)..
24/2/202513:30GLOBEPlus Therapeutics Announces Leadership Appointments for..
20/2/202523:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/2/202523:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/2/202523:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/2/202523:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/2/202523:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/2/202523:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/2/202513:30GLOBEPlus Therapeutics Appoints Dr. Michael Rosol as Chief..
18/2/202513:32EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
18/2/202513:30EDGAR2Form 8-K - Current report
18/2/202513:30GLOBEPlus Therapeutics Secures $5.7 Million Financing to Support..
10/2/202514:27EDGAR2Form SCHEDULE 13G/A - Statement of Beneficial Ownership by..
17/12/202413:30GLOBEPlus Therapeutics Presents Positive ReSPECT-LM Phase 1..
04/12/202413:30GLOBEPlus Therapeutics to Showcase ReSPECT-LM Phase 1 Interim..
03/12/202413:30GLOBEPlus Therapeutics Expands Strategic Agreement with Telix..
25/11/202413:30GLOBEPlus Therapeutics Presents Positive ReSPECT-LM Phase 1..
22/11/202413:30GLOBEPlus Therapeutics to Present Positive FORESEE Clinical Trial..
21/11/202413:30GLOBEPlus Therapeutics to Present Multi-Institutional Experience..
14/11/202422:15GLOBEPlus Therapeutics Reports Third Quarter 2024 Financial..
14/11/202422:12EDGAR2Form 8-K - Current report
14/11/202422:11EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
06/11/202413:30GLOBEPlus Therapeutics and SpectronRx Announce Radiotherapeutic..
05/11/202413:30GLOBEPlus Therapeutics to Announce Third Quarter Financial..
01/11/202413:30EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
01/11/202413:25EDGAR2Form 8-K - Current report
29/10/202412:30GLOBEPlus Therapeutics Showcases Leptomeningeal Metastases..
04/10/202422:11EDGAR2Form S-3 - Registration statement under Securities Act of..
01/10/202413:30GLOBEPlus Therapeutics Reports ReSPECT-GBM Clinical Trial Update..
18/9/202413:30GLOBEPlus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2..
17/9/202413:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/9/202413:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/9/202412:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/9/202412:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/9/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/9/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/9/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/9/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/9/202412:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/9/202422:52EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
06/9/202422:47EDGAR2Form 8-K - Current report
04/9/202413:30GLOBEPlus Therapeutics to Present at the H.C. Wainwright 26th..
23/8/202422:31EDGAR2Form S-8 - Securities to be offered to employees in employee..
15/8/202422:53EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
15/8/202422:50EDGAR2Form 8-K - Current report
14/8/202422:48EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
14/8/202422:31EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/8/202422:16GLOBEPlus Therapeutics Reports Second Quarter 2024 Financial..
14/8/202422:08EDGAR2Form 8-K - Current report
13/8/202413:30GLOBEPlus Therapeutics Presents Positive Clinical Trial Results..
Apertura: 0,98 Min: 0,7368 Max: 0,98
Chiusura: 1,08

La tua Cronologia

NASDAQ
PSTV
Plus Therapeutics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci